<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1405245296
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TELFAST 120 MG FILM COATED TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FEXOFENADINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        26.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANOFI WINTHROP INDUSTRIE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANOFI WINTHROP INDUSTRIE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 4901]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Opella Arabia Limited Co
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Sanofi Consumer Healthcare
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R06AX26
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Telfast contains an active ingredient called fexofenadine hydrochloride. It is one of a group of medicines called antihistamines.<br />Antihistamines help reduce allergic symptoms by preventing the effects of a substance called histamine, which your body produces when exposed to certain substances.<br />Telfast is a non-sedating antihistamine which means it has been shown not to cause drowsiness.<br />Telfast 120 mg tablets are used to relieve the symptoms of hayfever (seasonal allergic rhinitis) such as sneezing, itchy, watery or red eyes and itchy, blocked or runny nose in adults and children aged 12 years or older.<br />Your pharmacist or doctor may have recommended this medicine for another reason.<br />Ask your pharmacist or doctor if you have any questions about why this medicine has been recommended for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>Contraindications</strong>:</u><br />When you must not take it<br />Do not take Telfast if you are pregnant, intend to become pregnant, or if you are breastfeeding, unless advised to do so by a Doctor or Pharmacist.<br />Do not take Telfast if you have had an allergic reaction allergy to fexofenadine, terfenadine or any of the other ingredients in Telfast. These are listed at the end of this leaflet.<br />Do not give Telfast to children under 12 years of age.<br />Do not take Telfast after the expiry date (EXP.) printed on the pack or if the packaging is damaged or shows signs of tampering.<br />If you take it after the expiry date has passed, it may not work as well. If it has expired or is damaged, return it to your pharmacist for disposal.<br /><strong><u>Appropriate precautions for use; special warnings:</u></strong><br />Before you start to take it<br />You should inform your pharmacist or doctor if you have any allergies to any other medicines, foods, preservatives or dyes.<br />Your pharmacist or doctor will consider these points when recommending Telfast.<br /><strong>Taking other medicines</strong><br />Tell your pharmacist or doctor if you are taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food store.<br />Some medicines and Telfast may interfere with each other.<br />If you are taking apalutamide (a medicine to treat prostate cancer), as the effect of Telfast may be decreased.<br />Your pharmacist or doctor has more information on medicines to be careful with or to avoid while you are taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much to take</strong><br />For the relief of the symptoms of hayfever, the usual dosage for adults and children over 12 years of age is one Telfast 120 mg tablet daily when required.<br />Talk to your pharmacist or doctor if you are unsure what dose to take.<br />The dosage directed by your pharmacist or doctor may be different to the recommended dose. Do not take more than the dose your pharmacist or doctor has directed.<br /><strong>How to take it</strong><br />Take Telfast with a glass of water or as directed by your pharmacist or doctor. Telfast may be taken with or without food.<br /><strong>How long to take it</strong><br />The duration of treatment depends on the type and duration of your complaint. Talk to your pharmacist or doctor about how long to take Telfast.<br />If Telfast does not relieve your symptoms, do not take extra tablets. Tell your doctor or pharmacist.<br /><strong>If you take too much (overdose)</strong><br />If you think that you or someone else may have taken too much Telfast immediately telephone your doctor or pharmacist, or go to Accident and Emergency at your nearest hospital. Do this even if there are no signs of discomfort or poisoning.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Things you must do</strong><br />Tell all the doctors, dentists and pharmacists who are treating you that you are taking Telfast.<br />If you are about to be started on any new medicine, tell your Doctor or Pharmacist that you are taking Telfast.<br />If you are to have surgery that needs a general anaesthetic, tell the doctor or dentist that you are taking this medicine.<br />If you become pregnant while taking Telfast, consult your Doctor or Pharmacist.<br /><strong>Things you must not do</strong><br />Do not take more than the recommended dose unless your pharmacist or doctor tells you to. Do not give this medicine to anyone else, even if they have the same condition as you.<br />Do not use this medicine to treat any other complaints unless your pharmacist tells you to.</p><p>The National Pharmacovigilance Centre (NPC):<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/</p><p>&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your pharmacist or doctor as soon as possible if you do not feel well while taking Telfast, even if you do not think the problem is connected with the medicine or is not listed in this leaflet.<br />All medicines can cause side effects. Sometimes they are serious, but must of the time they are not. You may need medical treatment if you get some of the side effects. Although most people will not experience any, some of the side effects that may occur with Telfast are:<br />&bull; headache;<br />&bull; tiredness;<br />&bull; nausea;<br />&bull; indigestion;<br />&bull; dizziness;<br />&bull; drowsiness.<br />&bull; Blurred vision.<br />These same effects were seen in patients taking &ldquo;dummy&rdquo; or placebo capsules during clinical studies.<br />Ask your pharmacist or doctor to answer any questions you may have.<br /><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, your pharmacist or your nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>KEEP THIS MEDICINE OUT OF THE SIGHT AND REACH OF CHILDREN.<br />Storage<br />Keep your tablets in the blister pack until it is time to take them.<br />If you take the tablets out of the box or the blister pack they may not keep well. Keep this medicine in a cool, dry place where the temperature stays below 30&deg;C. Do not store it or any other medicine in the bathroom, near a sink.<br />Do not leave it in the car, or on a windowsill. Heat and damp can destroy some medicines.<br />A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.<br />Disposal<br />If your pharmacist or doctor tells you to stop taking Telfast, or if the product has passed its expiry date, ask your pharmacist what to do with any left over product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Telfast, 120 mg film-coated tablets contains
• The active substance is:
fexofenadine hydrochloride… ......................................................................................................... 120 mg
per tablet.
• The other ingredients are:
microcrystalline cellulose, pregelatinised maize starch, croscarmellose sodium, magnesium stearate, povidone, titanium dioxide, colloidal anhydrous silica, macrogol 400, Pigment Blend Pink PB1254, Pigment Blend Yellow PB1255, hypromellose.
Telfast 120 mg does not contain any gluten, lactose or preservatives.
What Telfast, 120 mg film-coated tablets looks like and contents of the pack
Telfast 120 mg are peach coloured and have a modified capsule shape.
Telfast 120 mg is available in blister packs of 10, 15 or 30 tablets. Not all pack size may be marketed in your country.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Operating Company</strong><br />Sanofi Consumer Healthcare<br />87 Yarraman Place<br />Virginia, QLD 4014, Australia</p><p><strong>Manufacturer</strong><br />sanofi winthrop industrie<br />30-36, avenue Gustave Eiffel<br />37100 Tours - France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                20 February 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي تلفاست على مادة فاعلة ت سمى هيدروكلوريد الفكسوفينادين تنتمي إلى مجموعة من الأدوية ت سمى مضادات الهيستامين .<br />تساه م مضادات الهيستامين في الحد من العوارض التحسسيّة الت ي تسبّبها مادة ت سمى الهيستامين ينتجها جسمك عندما يتعرض<br />لبع ض المواد .<br />تلفاست هو مضاد هيستامين غير مسكن مما يعني أ نّه ثبت عدم تسبّبه بالنعاس.<br />ت ستعمل أقراص تلفاست 120 ملغ لتخفيف عوارض حمى القش ) التهاب الأنف التحسسي الموسمي ( مثل الع طاس وحكة العينين أ و<br />تدمعهما أو احمرارهما، وحكة الأنف أو انسداده أو سيلانه لد ى البالغين والأطفال بعمر 12 سنة أو ما فوق .<br />ق د يكون الصيدلي أ و الطبيب وصف لك هذا الدواء لسبب آخر .<br />إسأ ل الصيدلي أو الطبيب إذ ا كا ن لديك أسئلة حول سبب وصف هذا الدواء لك .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>موانع الاستعمال :</strong></u><br /><strong>مت ى لا يجدر بك أخذ هذا الدواء</strong></p><p>لا تأخذي تلفاست إذا كنت حاملًا أو كنت تنوين الحمل أو إذا كنت مرضعة، إ لا إذا نصحك طبيب أو صيدلي باستعماله .<br />لا تأخذ تلفاست إذا سبق لك أن أ صبت بارتكاس تحسسي ضد الفيكسوفينادين أو الترفينادين أو ض دّ أي مكون آخر في تلفاست .<br />المكونا ت مذكورة في نهاية هذه النشرة</p><p>لا تعط تلفاست لأطفال ما دون ال &nbsp;12 من العمر .<br />لا تأخذ تلفاست بعد انقضاء تاريخ الصلاحيّة (EXP) المطبوع على العلبة أو إذا كان الغلاف متضررً ا أو فيه علامات عبث . إذا<br />أخذت الدواء بعد انقضاء تاريخ الصلاحيّة، قد لا يعطي مفعوله كما يجب . وإذا انقضت مدّة صلاحيّته أو كان متضررً ا، أعد ه<br />إل ى الصيدلي ليتخ لّص منه</p><p><u><strong>احتياطا ت خاصة للاستعمال؛ تحذيرات خاصة :</strong></u><br /><strong>قب ل أن تبدأ بأخذ الدواء</strong><br />يج ب أن ت علم الصيدلي أو الطبيب إذا كان لديك أي حساسيّات ضد أي أدوية أو أطعمة أو مواد حافظة أو أصباغ .<br />سو ف يأخذ الصيدل ي أو الطبيب هذه النقاط بعين الاعتبار عند وصف هذا الدواء</p><p><strong>أخذ أدوية أخرى</strong><br />أعل م الصيدلي أو الطبيب إذا كنت تأخذ أدوية أخرى، بما فيها أي دواء تشتريه بدون وصفة من الصيدليّة أو السوبرماركت أو<br />متج ر المواد الصحيّة الغذائيّة .<br />قد تتفاعل بعض الأدوية مع تلفاست.<br />إذا كنت تتناول أبالوتاميد )دواء لعلاج سرطان البروستاتا( ، فقد ينخفض تأثير تيلفاست .<br />لدى الصيدلي أو الطبيب المزيد من المعلومات حول الأدوية التي يجب توخي الحذر عند تناولها أو التي يجب تفاديها وأنت تأخذ<br />هذ ا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هي الكمي ة الواجب أخذها</strong><br />للتخفيف من أعراض حمى القش، تبلغ الجرعة العاديّة للبالغين والأطفال فوق عمر 12 سنة قرصا واحدًا من تلفاست 120 ملغ<br />يوم يًا عند الضرورة .<br />تحدّ ث إلى الصيدلي أو الطبيب إذا لم تكن متأكدًا من الجرعة التي عليك أخذها .<br />يمك ن أن يكون مقدار الجرعة الموصوف من الصيدلي أو الطبيب مختلف ا عن الجرعة الموصى بها .<br />لا تأخذ أكثر من الجرعة التي حدّدها الصيدل ي أو الطبيب</p><p><strong>كيف يؤخذ تلفاست</strong><br />خذ تلفاست مع كوب من الماء أو حسب تعليمات الصيدلي أو الطبيب .<br />يمك ن أخذ تلفاست مع الطعام أو بدونه</p><p><strong>ما هي مدة العلاج</strong></p><p>تتو قّف مدّة العلاج على نوع شكواك ومدّتها .<br />تحدّ ث إلى الطبيب أو الصيدلي حول المدّة التي يجب أن تأخذ تلفاست فيها .<br />إذ ا لم يخف ف تلفاست أعراضك، لا تأخذ أقراصا إضافيّة . أعلم الطبيب أو الصيدلي</p><p><strong>إذ ا أخذت كمي ة من تلفاست أكثر مما يجب (فرط الجرعة)</strong></p><p>إذ ا كنت تعتقد أ نّك أخذت أنت أو أخذ أح د آخر كميّة كبيرة من تلفاست، اتصل على الفور بالطبيب أو الصيدلي أو اذهب إلى قس م<br />الطوار ئ في المستشفى الأقرب . إفعل هذا ح تّى ولو لم تكن تعاني من أي علامات انزعاج أو تسمم .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>الأمو ر التي يجب عليك فعلها</strong></p><p>أعل م كل الأطبّاء وأطبّاء الأسنان والصيادلة الذين يعالجونك أ نّك تأخذ تلفاست .<br />إذ ا كنت على وشك البدء بأخذ دواء جديد، أعلم الطبيب أو الصيدلي أ نّك تأخذ تلفاست .<br />إذ ا كنت ستخضع لجراحة تحتاج إلى تخدير عام، أعلم الطبيب أو طبيب الأسنان أ نّك تأخذ هذا الدواء .<br />إذ ا أصبحت حاملًا وأنت تأخذي ن هذا الدواء، استشيري الطبيب أو الصيدلي .<br /><strong>الأمو ر التي لا ينبغي بك فعلها</strong><br />لا تأخذ أكثر من الجرعة الموصى بها إلّا إذا طلب منك الصيدل ي أو الطبيب ذلك .<br />لا تعط هذا الدواء لأي أحد آخر ، ح تّى ولو كانت حالته مثل حالتك .<br />لا تستعمل هذا الدواء لعلاج أي حالات أخرى إلّا إذا قال لك الصيدلي ذلك</p><p>المركز الوطني للتيقظ<br />الرقم المجاني 19999<br />البريد الإلكتروني : npc.drug@sfda.gov.sa<br />الموق ع الإلكتروني :&nbsp;https://ade.sfda.gov.sa</p><p>سانوفي لل تّيق ظ والسلامة الدوائية : KSA_Pharmacovigilance@sanofi.com</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أعلم الصيدلي أو الطبيب في أقرب وقت ممكن إذا كنت تشعر بأي انزعاج في خلا ل فترة أخذك تلفاست حتّى ولو لم تكن تعتقد<br />أ ن المشكلة مرتبطة بالدواء أو حت ى لو لم تكن مذكورة في هذه النشرة</p><p>يمكن أن تسبّب الأدوية ك لّها تأثيرات جانبيّة تكون خطيرة أحيا نًا، ولكن لا تكون كذلك في أكثريّة الأحيان . قد تحتاج إلى علاج<br />طبّ ي إذا أصبت ببعض التأثيرات الجانبيّة . بالرغم من أ أ كنثريّة الأشخاص لن يصابوا بأي تأثيرات جانبيّة، بعض التأثيرات<br />الجانبيّة التي يمكن أن تحص ل مع تلفاست هي الآتية</p><p>&bull; صداع .<br />&bull; تعب.<br />&bull; غثيان.<br />&bull; عسر هضم .<br />&bull; دوار.<br />&bull; نعاس .<br />&bull; رؤية مشوشة أو غير واضحه .</p><p>تمت ملاحظة هذه التأثيرات نفسها لدى مرضى يأخذون كبسولات دواء وهمي أثناء تجارب سريريّة .<br />أطلب من الصيدلي أو الطبيب الإجابة على أ ي أسئلة قد تراودك.</p><p><strong>الإبلاغ عن التأثيرات الجانبية</strong><br />إذا أصبت بأي تأثيرات جانبيّة، تحدّث إلى الطبيب أو الصيدلي أو الممرضة، ويتضمن هذا أي تأثيرات جانبيّة محتملة غير مذكورة في<br />هذه النشر ة . بالإبلاغ عن التأثيرات الجانبيّة، يمكن ك المساعد ة عل ى تزويد المزيد م ن المعلوما ت حو ل سلام ة هذ ا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحفظ هذا الدواء بعيدًا عن نظر الأطفال ومتناولهم .</p><p><strong>طريقة الحفظ</strong><br />إحف ظ أقراصك في علب ة الظروف ح تّى يحين وقت أخذها .<br />إذ ا أخرجت الأقراص من العلبة أو من الظرف قد لا يتم حفظها جيّدًا .<br />إحف ظ هذا الدواء في مكان بارد وجاف حيث تبقى الحرارة ما دون 30 درجة مئويّة .<br />لا تحفظ الدواء أو أي دواء آخر في الحمام، بالقرب من البالوعة .<br />لا تتركه في السيّارة أو على حاف ة النافذة .<br />ما الذي علي ك<br />يمك ن أن تتلف الحرارة والرطوب ة بعض الأدوية .<br />إ ن خزانة مقفلة تعلو عن الأر ض مترا ونصف المتر مكان جيّد لتخزين الأدوية .<br /><strong>التخلص</strong><br />إذ ا طلب منك الصيدلي أو الطبيب التوق ف عن أخذ تلفاست، أو إذا انقضى تاريخ صلاحيّة المنتج، إسأل الصيدل ي<br />فعل ه بأي منتج متبق</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">ماذ ا يحتوي تلفاست، 120 ملغ أقراص مغلفة<br />&bull; المادة الفاعلة هي :<br />هيدروكلوري د الفكسوفينادين 120 مل غ<br />في كل قرص.<br />&bull; المركبات الأخرى هي :<br />سلولو ز دقيق البلوريّة، نشا الذرة المسبق التهلمن، كروسكارميلوز الصوديوم، ستيارات المغنيزيوم، بوفيدون، ثاني أكسيد<br />التيتانيوم ، سيليكا غروانيّة لا مائيّة، ماكروغول 400 ، مزيج الصباغ زهري PB1254 ، مزيح الصباغ أصفر PB1255 ،<br />هبروميلوز .<br />لا يحتوي تلفاست 120 ملغ على الغلوتن أو على اللاكتوز أو على أي مواد حافظة .<br />م ا هو شكل تلفاست، 120 ملغ أقراص مغلفة ومحتويات العلبة<br />أقرا ص تلفاست 120 ملغ خوخية اللون ولها شكل كبسولة معدّلة .<br />تأت ي أقراص تلفاست 120 ملغ في علب ظروف من 10 أو 15 أو 30 قرصا .<br />ق د لا تكون أحجام العلب كلها مسوقة في بلدك</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة حاملة رخصة التسویق والشركة المشغّلة</strong><br />sSanofi Consumer Healthcare<br />87 Yarraman Place<br />Virginia, QLD 4014,<br />Australia<br /><strong>الشركة المصنعّة</strong><br />SANOFI WINTHROP INDUSTRIE<br />30-36, avenue Gustave Eiffel<br />37100 Tours<br />France</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مت مراجعة الأخيرة على هذ ه النشرة في ٢٠ نوفمبر ٢٠٢٣
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Telfast 120 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Telfast 6 – 11 Years Tablets*
Each tablet contains fexofenadine HCl 30 mg equivalent to 28 mg fexofenadine.
Telfast 60 mg Tablets
Each tablet contains fexofenadine HCl 60 mg equivalent to 56 mg fexofenadine.
Telfast 120 mg Tablets
Each tablet contains fexofenadine HCl 120 mg equivalent to 112 mg fexofenadine.
Telfast 180 mg Tablets
Each tablet contains fexofenadine HCl 180 mg equivalent to 168 mg fexofenadine.
Telfast Oral Liquid
Each mL of oral liquid contains fexofenadine HCl 6 mg (30 mg/ 5mL) equivalent to 5.6 mg
fexofenadine.
Excipients with known effect in Telfast Oral Liquid: propyl hydroxybenzoate, butyl
hydroxybenzoate and sucrose.
For the full list of excipients, see Section 6.1 List of excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Telfast 6 – 11 Years Tablets*
Peach, round, standard convex film-coated tablets engraved with ‘03’ on one side and a
scripted ‘e’ on the other.
Telfast 60mg Tablets
Peach, oval, double convex, tablets, debossed with ‘06’ on one side and a scripted ‘e’ on the
other.
Telfast 120 mg Tablets
Peach tablets with an ‘e’ on one side and plain on the other.
Telfast 180 mg Tablets
Peach tablets with an ‘e’ on one side and plain on the other.
Telfast Oral Liquid
White uniform aqueous suspension, with a raspberry cream flavour.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Oral Liquid</strong><br />Relief of symptoms associated with urticaria from 6 months of age. Relief of symptoms<br />associated with seasonal allergic rhinitis from 2 years of age.<br /><strong>6 &ndash; 11 Years Tablets*</strong><br />Relief of symptoms associated with seasonal allergic rhinitis, allergic rhinitis or urticaria in<br />children aged 6 to 11 years.<br /><strong>60 mg Tablets</strong><br />Relief of symptoms associated with allergic rhinitis in adults and children aged 12 years or<br />older.<br /><strong>120 mg Tablets</strong><br />Relief of symptoms associated with seasonal allergic rhinitis in adults and children aged 12<br />years or older.<br /><strong>180 mg Tablets</strong><br />Relief of symptoms associated with seasonal allergic rhinitis or urticaria in adults and<br />children aged 12 years or older.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Paediatrics</strong><br /><u>Allergic Rhinitis and Seasonal Allergic Rhinitis:</u><br />Children aged 2 to 11 years: 30 mg twice daily, when required.<br /><u>Urticaria:</u><br />Children aged 6 to 23 months: 15 mg twice daily, when required.<br />Children aged 2 to 11 years: 30 mg twice daily, when required.<br />Adults and Children aged 12 years or older<br /><u>Allergic Rhinitis:</u><br />60 mg twice daily, when required.<br /><u>Seasonal Allergic Rhinitis:</u><br />120 mg or 180 mg once daily, when required.<br /><u>Urticaria:</u><br />180 mg once daily, when required.<br />Dosage adjustment is not required in the elderly or in patients with hepatic or renal<br />impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Telfast is contraindicated in patients with a known hypersensitivity to fexofenadine,
terfenadine or any of its excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Use in renal impairment</strong><br />Dosage adjustment is not required in patients with renal impairment.<br /><strong>Use in hepatic impairment</strong><br />Dosage adjustment is not required in patients with hepatic impairment.<br /><strong>Use in the elderly</strong><br />Dosage adjustment is not required in the elderly.<br /><strong>Paediatric use</strong><br />Safety and effectiveness of Telfast has not been established in children under 2 years of age<br />for allergic rhinitis and under 6 months of age for chronic idiopathic urticaria.<br />Telfast 6 &ndash; 11 Years tablets* is intended for paediatric patients 6 to 11 years of age and<br />Telfast Oral Liquid for children from 6 months.<br /><strong>Effects on laboratory tests</strong><br />No data available</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As fexofenadine undergoes negligible hepatic biotransformation, it is unlikely to interact with<br />other drugs through hepatic metabolism.<br />The pharmacokinetics of fexofenadine HCl and pseudoephedrine are not altered when both<br />drugs are co-administered.<br />Fexofenadine is a P-glycoprotein (P-gp) and organic-anion-transporting polypeptide (OATP)<br />substrate. Concomitant use of fexofenadine with P-gp inhibitors or inducers can affect the<br />exposure to fexofenadine.<br />Coadministration of fexofenadine with P-gp inhibitors erythromycin or ketoconazole has<br />been found to result in a 2 - 3 times increase in the level of fexofenadine in plasma. The<br />changes were not accompanied by any effects on the QT interval and were not associated<br />with any increase in adverse events compared to the drugs given singly. Fexofenadine had no<br />effect on the pharmacokinetics of erythromycin or ketoconazole.<br />A clinical drug-drug interaction study showed that co-administration of apalutamide (a weak<br />inducer of P-gp) and a single oral dose of 30 mg fexofenadine resulted in a 30 % decrease in<br />AUC of fexofenadine.</p><p>No interaction between fexofenadine and omeprazole has been observed. However, the<br />administration of an antacid containing aluminium and magnesium hydroxide gel 15 minutes<br />prior to fexofenadine HCl causes a reduction in bioavailability, most likely due to binding in<br />the gastrointestinal tract. It is advisable to leave 2 hours between administration of<br />fexofenadine HCl and aluminium and magnesium hydroxide containing antacids.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effects on fertility</strong><br />In rat fertility studies, dose-related reductions in implants and increases in postimplantation<br />losses were observed at oral doses equal to or greater than 150 mg/kg of terfenadine<br />respectively; these doses produced plasma AUC values of fexofenadine that were equal to or<br />greater than three times the human therapeutic value respectively (based on a 60 mg twice<br />daily fexofenadine HCl dose).<br /><strong>Use in pregnancy</strong><br />Category B2. Reproductive toxicity of fexofenadine in animals was assessed through<br />terfenadine exposure. No evidence of teratogenicity was observed in animal reproduction<br />studies (rat and rabbit) when terfenadine was given at oral doses of up to 300 mg/kg/day<br />throughout organogenesis, which corresponds to levels of systemic fexofenadine exposure 4-<br />and 32-fold higher, respectively, than those anticipated in clinical use. Decreased pup weight<br />and survival occurred in rats when terfenadine was given at oral doses of 150 mg/kg/day and<br />above throughout pregnancy and lactation.<br />There are no studies in pregnant women exposed to fexofenadine alone or through the<br />administration of terfenadine.<br /><strong>Use in lactation</strong><br />Telfast is not recommended for nursing women unless, in the physician&rsquo;s judgment, the<br />potential benefit to the patient outweighs the potential risk to the infant. There are no data on<br />the content of human milk after administering fexofenadine. However, when terfenadine was<br />administered to nursing mothers, fexofenadine was found to cross into human breast milk.<br />Exposure of rats to fexofenadine and terfenadine through the administration of terfenadine at<br />dietary doses of 150 and 300 mg/kg/day throughout pregnancy and lactation (corresponding<br />to systemic exposure at levels (AUC) approximately 3- and 6-fold higher than those<br />anticipated in clinical use) caused decreased pup weight gain and survival. The relative risks<br />of these effects from terfenadine or fexofenadine are unknown. Effects on pups exposed to<br />fexofenadine only during lactation are unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effects of this medicine on a person&rsquo;s ability to drive and use machines were not assessed<br />as part of its registration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Telfast is generally well tolerated. In placebo-controlled trials involving seasonal allergic<br />rhinitis and chronic idiopathic urticaria patients, adverse events were comparable in</p><p>fexofenadine- and placebo-treated patients. The most common adverse events reported in<br />controlled clinical trials were headache, fatigue, dizziness or drowsiness and nausea. No<br />apparent dose trends were revealed in adverse events.<br />Events that have been reported during controlled trials involving seasonal allergic rhinitis and<br />chronic idiopathic urticaria patients with incidences less than 1% and similar to placebo, and<br />have been reported rarely during postmarketing surveillance include: fatigue, insomnia,<br />nervousness, and sleep disorders or paroniria. In rare cases, rash, urticaria, pruritus and<br />hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnoea,<br />flushing and systemic anaphylaxis have been reported.<br />Adverse events reported in placebo-controlled chronic idiopathic urticaria studies were<br />similar to those reported in placebo-controlled seasonal allergic rhinitis studies. In placebocontrolled<br />trials involving paediatric seasonal allergic rhinitis patients (6-11 years of age),<br />adverse events were similar to those observed in trials involving seasonal allergic rhinitis<br />patients 12 years and older.<br />In controlled clinical trials involving paediatric patients 6 months to 5 years of age, there<br />were no unexpected adverse events in patients treated with fexofenadine hydrochloride.<br />As with adults, the incidence of adverse events with fexofenadine in paediatric patients was<br />similar to placebo.</p><p>Eye disorders:<br />Vision blurred (unknown)</p><p>To reports any side effect(s):<br />Saudi Arabia:<br />&bull; The National Pharmacovigilance Centre (NPC):</p><p>- Fax: +966-11-205-7662<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/</p><p>&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p><p>Other GCC States:<br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical experience with a fexofenadine overdose. The maximum single dose<br />tested in clinical trials is 800 mg in six healthy subjects. In a multiple-dose study, doses of<br />690 mg every 12 hours for 28.5 days were given to three healthy subjects and, in another<br />study with forty subjects, a dose of 400 mg every 12 hours was given for 6.5 days. No<br />clinically significant adverse events were reported in these studies.<br />In the case of an overdose, standard measures to remove any unabsorbed drug should be<br />employed. Symptomatic and supportive treatment is recommended. Haemodialysis is not an<br />effective means of removing fexofenadine from plasma.<br />For general advice on management of overdose, contact the Poisons Information Centre,<br />telephone number 13 11 26 (Australia) or the National Poisons Centre, 0800 POISON or<br />0800 764 766 (New Zealand).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antihistamine for systemic use, ATC code: R06A X26<br /><strong>Mechanism of action</strong><br />The antihistaminic effects of fexofenadine have been demonstrated in animal systems in vitro<br />and in vivo. Oral administration of fexofenadine to guinea pigs, indicated that fexofenadine<br />antagonised histamine-induced skin wheals in a dose-dependent manner. Fexofenadine and<br />terfenadine antagonised the contractile effects of histamine in the guinea pig ileum in vitro.<br />In this model fexofenadine was found to be a more selective histamine antagonist than<br />terfenadine.<br />Fexofenadine inhibited antigen-induced bronchospasm in sensitised guinea pigs and, at high<br />doses (&gt;100-fold higher than those required for antihistaminic activity), inhibited histamine<br />release from peritoneal mast cells of the rat. In laboratory animals, no anticholinergic or<br />alpha-1-adrenergic receptor blocking effects were observed. Radiolabelled tissue<br />distribution studies in rat indicated that fexofenadine does not cross the blood-brain barrier.<br />Fexofenadine is not associated with significant ECG abnormalities. Studies have shown that<br />fexofenadine does not affect the action potential or ion channel currents (IK, ICa, INa) in<br />either guinea pig or neonatal rat myocytes. Fexofenadine was 583 times less potent than<br />terfenadine in blocking a delayed rectifier potassium channel cloned from human heart.<br />Additionally, doses of fexofenadine ten times greater than the dose of terfenadine that<br />produces prolongation of QTC intervals do not prolong QTC intervals in anaesthetised<br />rabbits and conscious dogs.</p><p><strong>Clinical trials</strong><br />An escalating acute dose study demonstrated antihistaminic activity via skin wheal and flare<br />inhibition at doses ranging from 40 mg to 800 mg, with maximum inhibition reaching a<br />plateau at a dose of 130 mg. An escalating repeat dose study demonstrated increasing skin<br />flare inhibition at twice daily doses ranging from 20 mg to 690 mg. During both acute dose<br />and repeat dose studies, an antihistaminic effect was observed within one hour, achieving<br />maximum effect within 2 - 4 hours and lasting a minimum of 12 hours. There was no<br />evidence of tolerance to these effects after 28 days of dosing.<br />In dose ranging studies, fexofenadine HCl was shown to relieve the symptoms of seasonal<br />allergic rhinitis, significantly reducing total symptom scores (including scores for sneezing,<br />rhinorrhoea, itchy nose, palate and/or throat, and itchy, watery, red eyes) over a dosage range<br />of 40 mg to 240 mg twice daily. In a double-blind, placebo-controlled trial of 208 patients<br />with chronic idiopathic urticaria, fexofenadine HCl 180 mg and 240 mg once daily for 6<br />weeks were found to significantly reduce total symptom scores (number of wheals (hives)<br />and pruritus).<br />In a double-blind, placebo-controlled clinical efficacy study involving 821 patients with<br />seasonal allergic rhinitis, fexofenadine HCl 120 mg and 180 mg once daily were found to be<br />significantly superior to placebo in relieving symptoms of seasonal allergic rhinitis, including<br />sneezing, rhinorrhoea, itchy nose, palate and/or throat, itchy, red or watery eyes and nasal<br />congestion, after 24 hours. There was no statistically significant difference in efficacy</p><p>between the two doses of fexofenadine, however the 180mg dose did show a trend toward<br />greater reduction in the mean total symptom score.<br />In a double blind placebo controlled study, 861 patients aged 12 &ndash; 65 years were randomised<br />to receive either 120 mg fexofenadine or 180 mg fexofenadine or placebo, once daily for a 2<br />week period. The primary efficacy measure was change from baseline of average total<br />symptom score. Both doses provided significant (p 0.05) improvement in symptoms of<br />seasonal allergic rhinitis, compared to placebo. While there was no statistically significant<br />difference in efficacy between the two doses, the 180 mg dose showed a trend toward greater<br />reduction in the average total symptom score.<br />In a double blind placebo controlled study investigating quality-of-life, 845 patients aged 12<br />65 years were randomised to receive 120 mg fexofenadine or 180 mg fexofenadine or<br />placebo once daily for a 2 week period. The primary efficacy measures were change from<br />baseline in a quality-of-life score and in a work / activity impairment score. Patients<br />receiving either 120 mg or 180 mg dose reported a significant (p 0.006) improvement in<br />overall quality-of-life score and a significant (p0.004) reduction in work / activity<br />impairment score, compared to placebo. No statistical comparison was made between the<br />effects of the two doses of fexofenadine.<br />The incidence of drowsiness in controlled clinical seasonal allergic rhinitis trials was similar<br />when comparing patients treated with fexofenadine and placebo. There was no dose-related<br />increase in drowsiness.<br />The effects of fexofenadine on the QTc interval have been investigated in a variety of studies<br />at doses up to 800 mg/day. There were no statistically significant differences in QTc interval<br />between fexofenadine and placebo treated patients. Similarly, there were no statistically<br />significant differences from placebo or dose-related changes in other ECG parameters as a<br />result of fexofenadine treatment.<br />Also, no statistically significant change in QTc intervals was observed in long term studies in<br />healthy subjects given fexofenadine HCl 60 mg twice daily for 6 months and 240 mg once<br />daily for 12 months, when compared to placebo.<br />Interaction studies in healthy volunteers between fexofenadine and erythromycin or<br />ketoconazole demonstrated that although the plasma AUC for fexofenadine increased<br />approximately 2 - 3 fold, there were no significant effects on mean or maximal QTc, nor were<br />there any effects on the incidence of adverse events. Although these plasma levels were<br />above those seen with the recommended dose, they were within the range of plasma levels<br />achieved in controlled dose ranging clinical trials. Fexofenadine had no effect on the<br />pharmacokinetics of erythromycin or ketoconazole (see 4.5 INTERACTIONS WITH<br />OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS for further<br />information).<br />Across the clinical trials, patients between the ages of 12 to 16 years have received doses<br />ranging from 20 mg to 240 mg twice daily. Adverse events were similar in this group<br />compared to patients above the age of 16 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fexofenadine HCl is rapidly absorbed into the body following oral administration, with tmax<br />occurring approximately 1 - 3 hours post-dose. Following administration of a single 60 mg<br />oral dose to healthy volunteers, fexofenadine HCl was rapidly absorbed, with a mean Cmax of<br />209 ng/mL. Following the administration of single oral doses of 120 mg and 180 mg<br />fexofenadine HCl, the mean Cmax values were approximately 427 ng/mL and 494 ng/mL,<br />respectively.<br />The absolute bioavailability following fexofenadine HCl administration was estimated to be<br />33%. Coadministration with food has no clinically significant effect on the absorption of<br />fexofenadine HCl.<br />The single and multiple dose pharmacokinetics of fexofenadine are linear for oral doses up to<br />120 mg bd. A dose of 240 mg bd produced a slightly greater than proportional increase<br />(8.8%) in steady state area under the curve, indicating that fexofenadine pharmacokinetics are<br />practically linear at daily doses between 40 mg and 240 mg. Fexofenadine is 60% to 70%<br />bound to plasma proteins.<br />Fexofenadine undergoes negligible metabolism. Following a single radiolabelled 60 mg oral<br />dose, approximately 80% and 11% of the total [14C]-fexofenadine dose was excreted in<br />faeces and urine respectively.<br />The plasma concentration vs. time profiles of fexofenadine follow a bi-exponential decline<br />with a mean terminal elimination half-life ranging from 14 to 15 hours following multiple<br />dosing.<br />The pharmacokinetics of fexofenadine in seasonal allergic rhinitis patients are similar to<br />those in healthy subjects.<br />Studies indicated that females may be exposed to higher plasma levels than males, however,<br />there was no indication of any difference in efficacy or in the frequency of adverse events<br />reported. Elderly patients, patients with hepatic impairment and patients with cardiac disease<br />exposed to fexofenadine by administration of terfenadine showed no statistically significant<br />differences in pharmacokinetic parameters for fexofenadine compared to healthy individuals.<br />Although peak plasma level and half-life were increased 68% and 15% respectively in elderly<br />patients and 54% and 19% respectively in patients with renal disease, regardless of disease<br />severity, these levels are within the range of plasma levels shown to be tolerated in short term<br />dose ranging trials.<br />The pharmacokinetics of fexofenadine in children and adults are similar, including tmax,<br />clearance (corrected for body surface area), t1/2 and volume of distribution, because<br />fexofenadine undergoes negligible metabolism, with 80% of the dose being eliminated<br />unchanged in the faeces. In contrast, other H1-receptor antagonists, which are extensively<br />metabolised in the hepatic cytochrome P450 system, usually have shorter half-life values in<br />children than adults.<br />In children, studies indicate that 30 or 60 mg fexofenadine suppresses the histamine induced<br />wheal and flare within 1 to 2 hours, with both doses producing similar mean maximal<br />suppression.</p><p>A dose of 5mL of Telfast Oral Liquid containing 30 mg of fexofenadine HCl is bioequivalent<br />to a 30 mg dose of Telfast tablets. Following oral administration of a 30 mg dose of Telfast<br />Oral Liquid to healthy adult subjects, the mean Cmax was 118.0 ng/mL and occurred at<br />approximately 1.0 hour.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Genotoxicity</strong><br />Fexofenadine showed no genotoxic activity in a series of assays for gene mutations and<br />chromosomal damage.<br /><strong>Carcinogenicity</strong><br />The carcinogenic potential and reproductive toxicity of fexofenadine HCl were assessed<br />using terfenadine studies. No evidence of carcinogenicity was observed when mice and rats<br />were given daily oral doses of 50 and 150 mg/kg of terfenadine for 18 and 24 months,<br />respectively; these doses resulted in plasma AUC values of fexofenadine that were two to<br />four times the human therapeutic value (based on a 60 mg twice daily fexofenadine HCl<br />dose).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Telfast tablets contain the following excipients: croscarmellose sodium, pregelatinised maize<br />starch, microcrystalline cellulose, magnesium stearate, hypromellose, povidone, titanium<br />dioxide, colloidal anhydrous silica, macrogol 400, Pigment Blend Pink PB1254 (ARTG PI<br />No.3225) and Pigment Blend Yellow PB1255 (ARTG PI No.3226).<br />Telfast Oral Liquid contains 6 mg/mL of fexofenadine HCl. Telfast Oral Liquid also contains<br />the following excipients: polypropylene glycol, edetate disodium, propyl hydroxybenzoate,<br />butyl hydroxybenzoate, xanthan gum, poloxamer 407, titanium dioxide, sodium phosphate<br />monobasic monohydrate, sodium phosphate dibasic heptahydrate, artificial raspberry cream<br />flavour (ARTG PI No. 12546), sucrose, xylitol and purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Incompatibilities were either not assessed or not identified as part of the registration of this<br />medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                In Australia, information on the shelf life can be found on the public summary of the
Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the
packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Telfast 120 mg Tablets</strong><br />Store below 30C.<br /><strong>Telfast 180 mg Tablets</strong><br />Store below 30C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Telfast 120 mg Tablets</strong><br />Available in blister packs of 10 and 30 tablets.<br /><strong>Telfast 180 mg Tablets</strong><br />Available in blister packs of 10, 30, 50 and 70 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In Australia, any unused medicine or waste material should be disposed of by taking to your<br />local pharmacy.</p><p>Fexofenadine occurs as a fine white to off-white powder. It is freely soluble in methanol,<br />soluble in ethanol, slightly soluble in water (3.6 mg/mL) and only very slightly soluble in<br />chloroform and hexane.<br />Fexofenadine is the carboxylic acid metabolite of terfenadine. It is an orally-active non<br />sedating histamine H1-receptor antagonist that is administered as the hydrochloride salt in<br />Telfast. The chemical name is benzeneacetic acid, 4-[1-hydroxy-4-[4-<br />(hydroxydiphenylmethyl)-1-piperidinyl]butyl]- ,-dimethyl-, hydrochloride.<br /><strong>Chemical structure</strong><br />Fexofenadine HCl is an equimolar mixture of two enantiomers. It has the following structure:</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sanofi Consumer Healthcare
87 Yarraman Place
Virginia, QLD 4014,
Australia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20 February 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>